At the news
? NEUTRALIMPACT 5/10 8-K filed Mar 12, 2026 at 08:11 ET
Atara Biotherapeutics announced that a Type A meeting with the FDA has been scheduled to discuss the Complete Response Letter for the Biologics License Application of tabelecleucel (tab-cel), developed with partner Pierre Fabre Pharmaceuticals. The company expects to provide a regulatory update in the second quarter of 2026.
- Atara Biotherapeutics announced a scheduled Type A meeting with the FDA on March 12, 2026.
- The meeting will address the Complete Response Letter (CRL) for the Biologics License Application (BLA) of tabelecleucel (tab-cel).
- The BLA is held by partner Pierre Fabre Pharmaceuticals, with Atara's support.
- The purpose is to discuss resubmission with additional efficacy data collected since the original submission.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access